Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder.
We evaluated the toxicity of high-dose local interleukin-2 (IL-2) in 18 patients not eligible for standard treatment of advanced transitional cell bladder carcinoma. Seven received continuous high-dose local natural IL-2 via pump system in the bladder for up to 420 days. 11 received cyclic high-dose local natural IL-2 or recombinant IL-2 for up to 420 days. Treatment was well tolerated and, considering the low rate of toxicity, could be offered in an outpatient setting. Except for local contrast-media hypersensitivity, no serious side-effects were observed. This study provides a basis for the non-toxic use of local IL-2 in future studies to evaluate effectiveness of the treatment or prophylaxis of patients with superficial bladder cancer in order to prevent recurrences.
Schwaibold
H
H
Department of Urology, University of Hamburg, Germany.
Huland
E
E
Heinzer
H
H
Schwuléra
U
U
Huland
H
H
D000283:Administration, Intravesical; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004804:Eosinophils / Q000166:cytology / Q000187:drug effects; D005260:Female; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000633:toxicity* / Q000652:urine; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010477:Perfusion; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000633:toxicity / Q000652:urine; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery
D016207:Cytokines; D007376:Interleukin-2; D011994:Recombinant Proteins